PRINCETON, N.J., & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the commercial launch of the first of the oncology testing services gained through its previously announced collaboration with Admera Health (October 30, 2014). Rosetta Genomics is now offering PGxOne™, a pharmacogenomics test that predicts patients’ responses to drugs based on their personal genetic makeup to avoid adverse effects; and EGFR and KRAS clinical sequencing, which provides genomic analysis of those tumor-based mutations from patient tissue to provide clinically relevant information relating to potential response to therapy, which is helpful for physicians, pathologists and researchers.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
